Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clavulanic Acid in Tobacco Use Disorder
NCT03713424Phase 2Active, not recruiting
- Sponsor
- University of Missouri
- Start
- Mar 2019
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tobacco Use Disorder (TUD) comparing Clav with Placebo (2 arms). Primary endpoints: Cigarette Smoking at 5 days and Self Reported Side Effects at 5 days. Started Mar 2019; status: active, not recruiting.
02
Drugs
clavulanic acid
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03713424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713424.